好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A unique presentation of Cerebrotendinous Xanthomatosis without tendinous xanthomas.
Neuromuscular and Clinical Neurophysiology (EMG)
P1 - Poster Session 1 (9:00 AM-5:00 PM)
411
To display the heterogeneity of Cerebrotendinous Xanthomatosis phenotypes.
Cerebrotendinous Xanthomatosis (CTX) is a rare autosomal recessive disorder due to CYP27A1 gene mutation which leads to decreased bile acid synthesis, and excess cholestanol production, often causing xanthomatous lesions in the tendons and brain. Early clinical manifestations can include bilateral juvenile cataracts and chronic diarrhea. It is a relatively heterogeneous disease which can present with epilepsy, parkinsonism, premature atherosclerosis, osteoporosis, pulmonary insufficiency, and polyneuropathy.
NA: Case report

Our patient is a 31-year-old male who presented with complaints of rapidly progressive lower extremity weakness, gait abnormality and diarrhea. He was referred to our center for possible diagnosis of amyotrophic lateral sclerosis (ALS). By the time of our initial evaluation, he was wheelchair bound with chronic diarrhea, and he was beginning to show signs of cognitive decline. Examination showed cognitive slowing, lower extremity weakness, diffuse hyperreflexia, and both axial and appendicular cerebellar signs. There was no corneal clouding or xanthomas. EDX exam showed diffusely slowed velocities at non-entrapment sites and prolonged F-wave latencies. EMG showed no evidence of active or chronic neurogenic changes. MRI of the brain was revealing for FLAIR hyperintensities in the bilateral dentate nuclei and posterior limbs of the internal capsule with extension into the corticospinal tracts and cerebral peduncles concerning for ALS or metabolic disorder. Given chronic diarrhea and MRI findings with dentate nucleus hyper-intensities, CTX was suspected and was confirmed by biochemical testing. We subsequently started Chenodeoxycholic Acid.

Cerebrotendinous Xanthomatosis is a rare but potentially treatable, phenotypically heterogeneous disorder, which can present without tendinous xanthomas. The imaging findings of T2 hyperintensities in the dentate nucleus, substantia nigra and globus are classic findings and the diagnosis should be suspected in any patient with this constellation of symptoms and classic MRI findings. 
Authors/Disclosures
Patricia Lee, MD (Usc)
PRESENTER
Dr. Lee has nothing to disclose.
Said R. Beydoun, MD, FAAN (University of Southern California Healthcare Consultation Center 2) Dr. Beydoun has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Janssen. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for CSL. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AstraZeneca. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Beydoun has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Takeda. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alnylam. Dr. Beydoun has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Beydoun has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for CSL. Dr. Beydoun has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for UCB. Dr. Beydoun has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Takeda. Dr. Beydoun has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for AstraZeneca. Dr. Beydoun has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Argenx. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Janssen. The institution of Dr. Beydoun has received research support from Abcuro. The institution of Dr. Beydoun has received research support from Sean Healy & AMG Center for ALS. The institution of Dr. Beydoun has received research support from Regeneron. The institution of Dr. Beydoun has received research support from RemeGen. The institution of Dr. Beydoun has received research support from Sanofi. The institution of Dr. Beydoun has received research support from Novartis.
Leila Darki, MD, FAAN (USC NeuroSciences) Dr. Darki has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Trinity Partner. Dr. Darki has received personal compensation in the range of $0-$499 for serving as a Consultant for Guide point Global. Dr. Darki has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Global Access Meetings. Dr. Darki has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx . Dr. Darki has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amylyx.